TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00881699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you
Description: Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Intervention
Description: Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
Study: NCT04387032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA Manipulations
Description: The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
Study: NCT02480998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG Flu Vaccine QIV 0.5mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Flu Vaccine TIV 0.5mL
Study: NCT05578313

Intervention type: DRUG
Intervention: Medical Cannabis
Description: Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
Study: NCT01352845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL dose, given at 0, 2 and 6 months
Study: NCT01638169

Intervention type: DEVICE
Intervention: adding a heel
Description: walking with and without heels on the gaitrite system
Study: NCT04066010

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile application (BP-n-Me)
Description: The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys.
Study: NCT03237429

Intervention type: DIAGNOSTIC_TEST
Intervention: bioimpedance spectroscopy
Description: Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery.

Intervention type: DIAGNOSTIC_TEST
Intervention: bioimpedance spectroscopy
Description: Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery.
Study: NCT03638336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILY robotic flexible ureteroscopy
Description: fragmentation of nephrolithiasis
Study: NCT02654041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined T3 and Methimazole treatment
Description: Oral administration of T3 and Methimazole
Study: NCT04154397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebellar transcranial stimulation
Description: Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebellar transcranial stimulation
Description: Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
Study: NCT03167125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Prompts
Description: This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Plus Live Prompts
Description: This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
Study: NCT00442949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization immediate PCI
Description: Catheterization immediate PCI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed PCI
Description: delayed PCI
Study: NCT01826448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Study: NCT00702611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Granulocyte Monocyte Apheresis (GMA-Apheresis)
Description: GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
Study: NCT01826448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Study: NCT01481506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
Study: NCT04143425

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-Tesla conventional magnetic resonance imaging
Description: T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced imaging without contrast use
Description: Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic susceptibility contrast-weighted imaging
Description: Cerebral blood volume and vessel architectural imaging parameters
Study: NCT04225312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized extended interval dosing of natalizumab
Description: Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard interval dosing
Description: Standard interval dosing in control group and historic group

Intervention type: DRUG
Group type: OTHER
Intervention: Standard interval dosing
Description: Standard interval dosing in control group and historic group
Study: NCT00757640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: prophylactic cholecystectomy during standard gastric surgery for cancer
Study: NCT02019758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Viscous Budesonide
Description: Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone MDI
Description: Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo slurry
Description: Slurry of sucralose - 4 mL twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhaler
Description: Placebo inhaler - 4 puffs twice daily
Study: NCT01865838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm (Sanofi, USA)
Description: Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
Study: NCT00511108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin phosphate
Description: sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
Study: NCT03779737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscular Resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory training
Study: NCT00511108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin phosphate
Description: sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: pioglitazone
Description: pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to pioglitazone
Description: pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study: NCT03779737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual training
Study: NCT03860662

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nociceptor flexor reflex
Description: The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
Study: NCT00702611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Monocyte Apheresis (GMA-Apheresis)
Description: GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
Study: NCT01010061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
Study: NCT00511108

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo to pioglitazone
Description: pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo to sitagliptin
Description: sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo to sitagliptin
Description: sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Study: NCT02235168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: six minute walking test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: six minute walking test
Study: NCT03313856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guazuma Ulmifolia plus Tecoma Stans
Description: Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcinaned magnesia
Description: Calcined magnesia 400 mg per capsule
Study: NCT03638713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: colonoscopy first
Description: Received water exchange colonoscopy followed by EGD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EGD first
Description: Received EGD followed by water exchange colonoscopy
Study: NCT03322085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation or cryoballoon
Description: Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation or cryoballoon
Description: Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation or cryoballoon
Description: Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
Study: NCT01399255

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Dosage form- Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Dosage form- Subcutaneous Injection
Study: NCT01055457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vistakon Investigational Multi-Purpose Solution II
Description: contact lens care solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: contact lens care solution
Study: NCT02542670

Intervention type: GENETIC
Intervention: Whole genome sequencing
Description: At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.

Intervention type: GENETIC
Intervention: Whole genome sequencing
Description: At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.

Intervention type: GENETIC
Intervention: Whole genome sequencing
Description: At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
Study: NCT00866060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: 20mg memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: 20mg memantine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10mg donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 10mg donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo donepezil
Description: Placebo donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo donepezil
Description: Placebo donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo memantine
Description: Placebo memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo memantine
Description: Placebo memantine
Study: NCT02927184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03825107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patching
Description: covering the fellow eye with an eyepatch to force use of the amblyopic eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dichoptic videos
Description: watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
Study: NCT03735121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in arm or cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in arm or cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in arm or cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in arm or cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in arm or cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Study: NCT06090929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS
Description: STN-DBS was implanted according normal process
Study: NCT00148525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory
Description: 6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal system theory
Description: This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.